Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Darcy

Showing results (191-200 of 222) with videos related to

Pageof 23
Sort By:
Cancer Medicine|July 6, 2019
Final analysis of a phase I/IIa trial of the folate-binding protein-derived E39 peptide vaccine to prevent recurrence in ovarian and endometrial cancer patientsTommy A Brown, Kevin Byrd, Timothy J Vreeland, et al.
Journal of Proteome Research|March 10, 2015
Elevated AKAP12 in paclitaxel-resistant serous ovarian cancer cells is prognostic and predictive of poor survival in patientsNicholas W Bateman, Elizabeth Jaworski, Wei Ao, et al.
Scientific Reports|May 1, 2021
Proteogenomic landscape of uterine leiomyomas from hereditary leiomyomatosis and renal cell cancer patientsNicholas W Bateman, Christopher M Tarney, Tamara Abulez, et al.
Cancers|March 13, 2024
Immuno-Molecular Targeted Therapy Use and Survival Benefit in Patients with Stage IVB Cervical Carcinoma in Commission on Cancer<sup>®</sup>-Accredited Facilities in the United StatesCollin A Sitler, Chunqiao Tian, Chad A Hamilton, et al.
Oncotarget|November 17, 2016
Interim analysis of a phase I/IIa trial assessing E39+GM-CSF, a folate binding protein vaccine, to prevent recurrence in ovarian and endometrial cancer patientsDoreen O Jackson, Kevin Byrd, Timothy J Vreeland, et al.
Clinical Pharmacology and Therapeutics|March 7, 2019
From Discovery to Practice and Survivorship: Building a National Real-World Data Learning Healthcare Framework for Military and Veteran Cancer PatientsJerry S H Lee, Kathleen M Darcy, Hai Hu, et al.
Gynecologic Oncology|March 5, 2019
GOG 8020/210: Risk stratification of lymph node metastasis, disease progression and survival using single nucleotide polymorphisms in endometrial cancer: An NRG oncology/gynecologic oncology group studyRebecca A Brooks, David S Tritchler, Kathleen M Darcy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 22, 2016
Clinicopathologic Significance of Mismatch Repair Defects in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group StudyD Scott McMeekin, David L Tritchler, David E Cohn, et al.
Gynecologic Oncology|August 28, 2023
Metronomic dosing of ovarian cancer cells with the ATR inhibitor AZD6738 leads to loss of CDC25A expression and resistance to ATRi treatmentWei Ao, Hong Im Kim, Domenic Tommarello, et al.
Gynecologic Oncology|February 10, 2021
Clinical significance of homologous recombination deficiency score testing in endometrial CancerJean H Siedel, Kari L Ring, Wei Hu, et al.
Pageof 23

Showing results (191-200 of 222) with videos related to

Sort By:
Pageof 23
Cancer Medicine|July 6, 2019
Final analysis of a phase I/IIa trial of the folate-binding protein-derived E39 peptide vaccine to prevent recurrence in ovarian and endometrial cancer patientsTommy A Brown, Kevin Byrd, Timothy J Vreeland, et al.
Journal of Proteome Research|March 10, 2015
Elevated AKAP12 in paclitaxel-resistant serous ovarian cancer cells is prognostic and predictive of poor survival in patientsNicholas W Bateman, Elizabeth Jaworski, Wei Ao, et al.
Scientific Reports|May 1, 2021
Proteogenomic landscape of uterine leiomyomas from hereditary leiomyomatosis and renal cell cancer patientsNicholas W Bateman, Christopher M Tarney, Tamara Abulez, et al.
Cancers|March 13, 2024
Immuno-Molecular Targeted Therapy Use and Survival Benefit in Patients with Stage IVB Cervical Carcinoma in Commission on Cancer<sup>®</sup>-Accredited Facilities in the United StatesCollin A Sitler, Chunqiao Tian, Chad A Hamilton, et al.
Oncotarget|November 17, 2016
Interim analysis of a phase I/IIa trial assessing E39+GM-CSF, a folate binding protein vaccine, to prevent recurrence in ovarian and endometrial cancer patientsDoreen O Jackson, Kevin Byrd, Timothy J Vreeland, et al.
Clinical Pharmacology and Therapeutics|March 7, 2019
From Discovery to Practice and Survivorship: Building a National Real-World Data Learning Healthcare Framework for Military and Veteran Cancer PatientsJerry S H Lee, Kathleen M Darcy, Hai Hu, et al.
Gynecologic Oncology|March 5, 2019
GOG 8020/210: Risk stratification of lymph node metastasis, disease progression and survival using single nucleotide polymorphisms in endometrial cancer: An NRG oncology/gynecologic oncology group studyRebecca A Brooks, David S Tritchler, Kathleen M Darcy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 22, 2016
Clinicopathologic Significance of Mismatch Repair Defects in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group StudyD Scott McMeekin, David L Tritchler, David E Cohn, et al.
Gynecologic Oncology|August 28, 2023
Metronomic dosing of ovarian cancer cells with the ATR inhibitor AZD6738 leads to loss of CDC25A expression and resistance to ATRi treatmentWei Ao, Hong Im Kim, Domenic Tommarello, et al.
Gynecologic Oncology|February 10, 2021
Clinical significance of homologous recombination deficiency score testing in endometrial CancerJean H Siedel, Kari L Ring, Wei Hu, et al.
Pageof 23